Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US-2017044265-A1 · Feb 16, 2017 · US
Anti-CD38 antibodies for treatment of acute myeloid leukemia
US10793630B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10793630-B2 |
| Application number | US-201514956890-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 2, 2015 |
| Priority date | Dec 4, 2014 |
| Publication date | Oct 6, 2020 |
| Grant date | Oct 6, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to methods of treatment of acute myeloid leukemia with anti-CD38 antibodies.
First claim
Opening claim text (preview).
We claim: 1. A method of treating a subject having relapsed or refractory acute myeloid leukemia (AML), comprising administering to the subject in need thereof an anti-CD38 antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 4 and a light chain variable region (VL) of SEQ ID NO: 5 for a time sufficient to treat relapsed or refractory AML, wherein the subject has been treated with idarubicin, cytarabine or hydroxyurea, wherein the AML is AML with at least one mutation in a gene selected from the group consisting of fins-related tyrosine kinase 3 (FLT3), nucleophosmin (NPM1), isocitrate dehydrogenase 2 (IDH2), DNA (cytosine-5) methyltransferase 3 (DNMT3A) and CCAAT/enhancer binding protein alpha (CEBPA). 2. The method of claim 1 , wherein the anti-CD38 antibody comprising the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5 is an IgG1, IgG2, IgG3 or IgG4 isotype. 3. The method of claim 2 , wherein the anti-CD38 antibody comprising the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5 comprises the heavy chain of SEQ ID NO: 12 and the light chain of SEQ ID NO: 13. 4. The method of claim 1 , wherein the mutation in FLT3 is FLT3-ITD, the mutation in IDH2 is R140Q or the mutation in DNMT3A is R882H.
Assignees
Inventors
Classifications
CD38 not IgG · CPC title
- C07K16/2896Primary
against molecules with a "CD"-designation, not provided for elsewhere · CPC title
- C07K16/28Primary
against receptors, cell surface antigens or cell surface determinants · CPC title
specific for leukemia · CPC title
- A61P35/00Primary
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10793630B2 cover?
- The present invention relates to methods of treatment of acute myeloid leukemia with anti-CD38 antibodies.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2896. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).